Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting
05. Oktober 2022 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics to Participate at Upcoming September Investor Conferences
02. September 2022 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development...
Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8αβ T Cells from TCR-CAR+ Induced Pluripotent Stem Cells
09. August 2022 08:00 ET
|
Fate Therapeutics, Inc.
TCR-CAR+ iPSC-derived CD8αβ T Cells Induced Complete and Durable Responses In Vivo in Systemic Leukemia Model Cell-surface Markers, Gene Transcription Profile, and In Vivo Anti-tumor Activity of...
Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
03. August 2022 16:01 ET
|
Fate Therapeutics, Inc.
FT596+R Enrollment Ongoing in Multi-dose, Multi-cycle Cohorts for R/R BCL; Initiated Study Start-up for Investigation of FT596+R-CHOP in Newly-diagnosed Patients with Aggressive BCL FT516 RMAT...
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Results
25. Juli 2022 16:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer
30. Juni 2022 16:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-derived CAR NK and CAR T-Cell Cancer Immunotherapies
28. Juni 2022 07:00 ET
|
Fate Therapeutics, Inc.
ONO to Contribute Novel Binding Domains for a Second Solid Tumor Antigen to the Collaboration Expanded Partnership Enables Development of both CAR NK and CAR T-cell Collaboration Candidates for Solid...
Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
03. Juni 2022 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
Fate Therapeutics to Present at Upcoming May Investor Conferences
06. Mai 2022 16:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, May 06, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress
04. Mai 2022 16:01 ET
|
Fate Therapeutics, Inc.
FT596+R Enrollment Ongoing in Single- and Multi-dose, Multi-cycle Cohorts for R/R BCL FT596+R-CHOP Clinical Protocol for First-line Investigation to be Submitted to FDA in 2Q22 FT819 Enrollment...